Bradesi Sylvie, Tillisch Kirsten, Mayer Emeran
Center for Neurovisceral Sciences & Women's Health, CURE: Digestive Diseases Research Center, UCLA Division of Digestive Diseases, GLA VA HC Bldg., 115/CURE, 11301 Wilshire Blvd., Los Angeles, California 90073, USA.
Expert Opin Emerg Drugs. 2006 May;11(2):293-313. doi: 10.1517/14728214.11.2.293.
Irritable bowel syndrome (IBS) is one of the most common chronic gastrointestinal disorders, yet its pathophysiology is incompletely understood and pharmacological treatments remain unsatisfactory. Current therapeutic choices include a range of drugs aimed at normalising bowel habits, reducing pain or treating comorbid psychological symptoms. However, this individual symptom-targeted approach remains unsatisfactory in terms of global symptom relief and patient satisfaction. In the last decade, further characterisation of IBS pathophysiology has provided new and exciting targets at different levels of the brain-gut axis for the development of several candidate drugs. Advances in clinical trial design will help to evaluate these compounds in different IBS patient populations.
肠易激综合征（IBS）是最常见的慢性胃肠道疾病之一，但其病理生理学尚未完全明确，药物治疗效果仍不尽人意。目前的治疗选择包括一系列旨在使排便习惯正常化、减轻疼痛或治疗合并的心理症状的药物。然而，这种针对个体症状的治疗方法在整体症状缓解和患者满意度方面仍不尽人意。在过去十年中，对IBS病理生理学的进一步研究在脑-肠轴的不同水平上提供了新的、令人兴奋的靶点，用于开发几种候选药物。临床试验设计的进展将有助于在不同的IBS患者群体中评估这些化合物。
